Ocular Therapeutix (OCUL) Long-Term Deferred Tax (2013)

Ocular Therapeutix (OCUL) recorded quarterly Long-Term Deferred Tax of $25.8 million in Q4 2013.

Ocular Therapeutix (OCUL) Long-Term Deferred Tax (2013) Analysis & Trends

Ocular Therapeutix's Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $25.8 million for Q4 2013.

In Q4 2013, Long-Term Deferred Tax changed N/A year-over-year to $25.8 million; the TTM figure through Dec 2013 stood at $25.8 million (changed N/A YoY), while the FY2013 annual figure was $25.8 million, changed N/A from the prior year.
Long-Term Deferred Tax was $25.8 million for Q4 2013 at Ocular Therapeutix.
In the past five years, Long-Term Deferred Tax ranged from a high of $25.8 million in Q4 2013 to a low of $25.8 million in Q4 2013.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Ocular Therapeutix	2.12 Bn	2.12 Bn	9.46 Mn

Historic Data

Download Data

Date	Value
Dec 31, 2013	25.78 Mn